Share This Page
Anti-anginal Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Anti-anginal
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 11,510,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 12,161,761 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 10,898,444 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Anti-Anginal Drugs
Summary
The anti-anginal drug market, integral to cardiovascular therapeutics, is experiencing evolving dynamics driven by demographic shifts, technological advancements, and regulatory changes. Patent protection remains a key competitive factor, influencing market entry, innovation, and pricing strategies. This report provides comprehensive insights into the current market landscape, patent protections, key players, and future outlook for anti-anginal medications.
What Are the Key Market Drivers in the Anti-Anginal Drug Segment?
| Factor | Impact | Details |
|---|---|---|
| Aging Population | Increases demand for anti-anginal therapies | WHO estimates that individuals aged 60+ will double by 2050. |
| Rising Prevalence of CAD | Coronary artery disease (CAD) remains the primary indication | Over 126 million cases globally (2022); stagnant incidence rates but increased treatment needs. |
| Advancements in Drug Formulations | Improved efficacy and patient compliance | Sustained-release formulations, combination drugs, and novel delivery methods. |
| Healthcare Infrastructure Growth | Expanding access to treatment in emerging markets | Growth in Asia-Pacific, Latin America, and Eastern Europe. |
| Expiry of Patent Exclusivities | Generic entry increases price competition | Notably impacts major brands like Ranolazine, Isosorbide dinitrate. |
What Are the Main Types of Anti-Anginal Drugs?
| Category | Mechanism of Action | Examples | Market Share (2022) | Notes |
|---|---|---|---|---|
| Nitrates | Dilate coronary vessels | Isosorbide dinitrate, Nitroglycerin | 35% | Widely used for acute and chronic relief. |
| Beta-Blockers | Reduce cardiac workload | Metoprolol, Atenolol | 25% | First-line therapy; generic availability. |
| Calcium Channel Blockers | Vasodilation, decreased myocardial workload | Amlodipine, Diltiazem | 20% | Used for both stable and vasospastic angina. |
| Ranolazine | Modulates myocardial metabolism | Ranolazine | 10% | Emerging class with specific indications. |
| Other (e.g., Nicorandil, Ivabradine) | Various mechanisms | Nicorandil, Ivabradine | 10% | Niche roles or emerging therapies. |
Patent Landscape: Key Patents and Their Expirations
Major Patents in Anti-Anginal Drugs
| Drug / Class | Patent Number | Patent Expiration Year | Type of Patent | Protection Scope |
|---|---|---|---|---|
| Ranolazine (Ranexa) | US 7,019,084 | 2029 | Composition, Formulation | Unique formulation method; polymorphic patterns |
| Isosorbide Dinitrate | US 4,382,841 | 2022 (various extensions) | Device, Composition | Extended formulations and delivery devices |
| Amlodipine | US 4,636,524 | 2020 | Use, Formulation | Formulation patents expired; brand protection ongoing in some regions |
| Nicorandil | US 4,455,409 | 2016 | Compound patent | Patent expiration in multiple jurisdictions |
| Ivabradine | US 7,622,480 | 2021 | Compound patent | Subject to patent litigation; some extensions granted |
Patent Expiration Trends
- Many foundational patents on classic nitrates expired between 2015–2022, opening avenues for generic manufacturers.
- Patents on newer classes (Ranolazine, Ivabradine) expected to expire between 2029–2030.
- The landscape indicates increasing patent expiry activity, which could catalyze generic competition and market pricing pressures.
Competitive Landscape and Key Players
| Company | Major Products | Market Share (2022) | Key Patent Holdings | Recent Strategic Moves |
|---|---|---|---|---|
| Novartis | Ranexa (Ranolazine) | 15% | Multiple patents, including method patents | Focus on novel formulations and combination therapies |
| Pfizer | Nitroglycerin products | 12% | Expired or expiring patents | Generic manufacturing dominates |
| Bayer | Amlodipine, Nicardipine | 10% | Many formulations now off patent | Diversification into combination drugs |
| Sanofi | Ivabradine | 8% | Patent expirations in 2021–2022 | Expanding licensed sales globally |
| Upstream innovators | Biotech startups / generics | Remaining 55% | Focus on generics and biosimilars | Entry of biosimilar and OTC products |
Market Trends and Future Outlook
Emerging Therapeutic Approaches
- Biologic and Gene Therapies: Early-stage research on gene editing for vascular repair.
- Combination Drugs: Fixed-dose combinations of nitrates and calcium channel blockers gaining popularity for adherence.
- Digital and Delivery Innovations: Transdermal patches, nanotechnology, and smart delivery systems.
Regulatory and Policy Factors
- Patent Linkage and Data Exclusivity: Transitioning markets enforcing stronger patent linkage, delaying generic entry.
- Pricing Regulations: Governments in Europe and Asia adopting price caps influencing profit margins.
- Orphan and Fast-Track Designations: Promoting development of niche therapies, especially for refractory angina.
Comparison of Market Dynamics: Developed vs. Emerging Markets
| Region | Market Size (2022) | Patent Activity | Regulatory Environment | Market Drivers |
|---|---|---|---|---|
| North America | USD 3.5 billion | High; IP protections robust | Strict; EMA/FDA | Innovation, cost, and reimbursement policies |
| Europe | USD 2.8 billion | High; similar to US | Stringent | Reimbursement, clinical guidelines |
| Asia-Pacific | USD 1.9 billion | Moderate; increasing patent filings | Variable; evolving | Growing healthcare access, local manufacturing |
| Latin America | USD 0.6 billion | Low; patent filings limited | Medium to relaxed | Cost-conscious healthcare, off-patent generics |
FAQs
-
How does patent expiry influence drug market competition in anti-anginal therapies?
Patent expirations typically lead to generic entry, lowering prices and increasing accessibility. However, some formulations may be protected by secondary patents or exclusivities, delaying generic competition. -
What are the key factors driving innovation in anti-anginal drugs?
Advances in drug delivery systems, focus on refractory and microvascular angina, and the integration of digital health tools are primary innovation drivers. -
Which anti-anginal drugs are most affected by patent expirations in the next five years?
Ranolazine (2029), Ivabradine (2021), and older nitrates and calcium channel blockers approaching patent expiration will face increased generic competition. -
How are biosimilars impacting the anti-anginal drug market?
Currently limited, as most anti-anginal drugs are small molecules. Development of biosimilar biologics for related metabolic or vascular targets is emerging. -
What regulatory challenges exist for new anti-anginal therapies?
Demonstrating significant clinical benefit over existing therapies, managing high costs of clinical trials, and navigating patent litigations remain key challenges.
Key Takeaways
- The anti-anginal drug market's growth is primarily driven by demographic shifts and increasing CAD prevalence.
- Patent expirations are facilitating a surge in generic and biosimilar options, intensifying price competition.
- Innovation focus is shifting toward combination therapies, improved delivery systems, and targeted biologics.
- Regional disparities influence market dynamics, with mature markets emphasizing innovation and emerging markets prioritizing affordability.
- Strategic patent management and early R&D investment are crucial for maintaining competitive advantage.
References
- World Health Organization. Cardiovascular Diseases (2022).
- Company Annual Reports (2022–2023).
- Patent databases (USPTO, EPO, WIPO).
- Market research reports – IQVIA, GlobalData (2022).
- Regulatory agency guidelines (FDA, EMA).
More… ↓
